Loading...
NPI 1063455822 · Honolulu, HI · Community/Retail Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Longs Drug Stores California LLC is a community/retail pharmacy provider located in Honolulu, Hawaii. This profile covers 10 Medicare and 10 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Longs Drug Stores California LLC |
| Address | 2750 Woodlawn Dr |
| City | Honolulu |
| State | HI |
| ZIP | 96822 |
| Taxonomy | Community/Retail Pharmacy |
| NPI Enumerated | June 13, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $358.5K |
| Medicaid | $33K |
LONGS DRUG STORES CALIFORNIA LLC presents as a retail/community pharmacy whose Medicare billing is dominated by immunization and COVID-related services: Medicare top codes include 91322 ($104.7K revenue, 29.1%), K1034 ($97K revenue, 27.0%), and 90694 ($37.8K revenue, 10.5%), reflecting vaccine administration and high-volume distribution of nonprescription COVID self-tests. This mix indicates on-site vaccination delivery plus point-of-care or over-the-counter test fulfillment as primary service lines driving payer revenue.
Revenue concentration on Medicare is high: the precomputed top-3 Medicare codes account for 66.7% of this provider's total Medicare revenue, centering Medicare receipts around COVID vaccination, COVID test provision, and seasonal influenza immunizations. That concentration means changes in vaccine demand or test reimbursement could materially swing the provider's Medicare income.
On Medicaid the top codes are more opaque because two of the three have no descriptions (0012A and 0011A), but they nevertheless account for a large share of that payer mix: the precomputed top-3 Medicaid codes represent 61.1% of Medicaid revenue with 0012A ($9.3K, 28.0%), 0011A ($6.2K, 18.7%), and 91322 ($4.8K, 14.4%) driving most Medicaid billing. The presence of 91322 among the Medicaid top codes shows the same vaccine service line is monetized across payers, while the unnamed codes suggest additional programmatic or product-specific Medicaid activity.
Payer mix is skewed strongly toward Medicare in scale: Total Medicare revenue is $358.5K versus Total Medicaid revenue of $33K, so Medicare dominates the provider's reported public-payer business. This profile indicates the entity functions effectively as a Medicare-focused immunization/test vendor with a smaller Medicaid footprint rather than a balanced dual-payer operation.
National competitive standing on key Medicare codes is relatively strong by rank: 91322 is ranked #139 of 29357 providers nationally (100th percentile; typical, unremarkable volume for this code) and K1034 is #341 of 30143 (99th percentile; typical, unremarkable volume for this code), placing the pharmacy among high-volume national peers for these products even as the dataset characterizes those volumes as "typical, unremarkable volume." Those high ranks suggest the provider achieves notable absolute volumes for COVID vaccine and test codes compared with most individual providers.
State-level competitiveness on Medicaid is modest-to-solid for the unnamed top codes: 0012A and 0011A each rank #21 of 88 providers in-state (77th percentile; typical, unremarkable volume for these codes), indicating a meaningful but not dominant presence in Hawaii for those billed items. By contrast, 91322 on Medicaid ranks #19 of 32 providers in-state (42th percentile; typical, unremarkable volume for this code), implying Medicaid COVID vaccine activity is comparatively limited versus other in-state vaccinators.
The provider also shows a diversified influenza and pneumococcal vaccine mix that supplements its COVID-related business: example Medicare entries include G0008 ($25.9K, 7.2%), 90662 ($24.8K, 6.9%), and 90677 ($20.7K, 5.8%), indicating routine seasonal and adult immunization services contribute meaningfully to revenue. This pattern is consistent with a community pharmacy that executes both seasonal vaccine campaigns and targeted adult immunizations alongside COVID services.
Operational tenure is long-standing: the NPI was enumerated on 2006-06-13 (~20 years ago), which supports interpretation of the billing patterns as stemming from an established retail pharmacy presence rather than a recent entrant or short-term operation. That longevity, combined with concentrated vaccine/test revenue, suggests an entrenched service model focused on immunizations and COVID test distribution.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 730 | $140 | $104.7K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 8,820 | $10 | $97K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 500 | $80 | $37.8K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 730 | $40 | $31.5K |
| G0008 | Administration of influenza virus vaccine | 860 | $30 | $25.9K |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 350 | $70 | $24.8K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 70 | $280 | $20.7K |
| 0134A | N/A | 370 | $40 | $16K |
| G0009 | Administration of pneumococcal vaccine | 70 | $10 | $570 |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 10 | $20 | $260 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 10 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 0012A | N/A | 240 | $40 | $9.3K |
| 0011A | N/A | 260 | $20 | $6.2K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 40 | $130 | $4.8K |
| 0064A | N/A | 80 | $40 | $3.3K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 270 | $10 | $3.3K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 150 | $20 | $2.6K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 40 | $40 | $1.5K |
| 0134A | N/A | 30 | $40 | $1.4K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 20 | $20 | $550 |
| 90656 | This code represents a preservative–free trivalent influenza vaccine product containing split virus components. It is administered into the muscle in a 0.5 mL dosage. | 20 | $20 | $290 |
How this provider's Medicaid billing volume and revenue compare to other Hawaii providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Hawaii median
10 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 82 | 230 | 140 | $20 | $16.1K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 19 | 30 | 50 | $110 | $7.7K |
| 0012A | N/A | 21 | 90 | 70 | $30 | $5.6K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 77 | 180 | 120 | $10 | $4.7K |
| 0011A | N/A | 21 | 90 | 80 | $20 | $4.4K |
| 0064A | N/A | 38 | 100 | 60 | $30 | $3.2K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 33 | 60 | 50 | $30 | $2.8K |
| 0134A | N/A | 21 | 40 | 30 | $30 | $1.5K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 43 | 60 | 50 | $20 | $1.3K |
| 90656 | This code represents a preservative–free trivalent influenza vaccine product containing split virus components. It is administered into the muscle in a 0.5 mL dosage. | 60 | 80 | 40 | $10 | $1.2K |
Other providers in the same ZIP code as Longs Drug Stores California LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Catholic Charities Hawaii | HI | Community/Behavioral Health Agency | $0 | $348.2K |
| Emily Bordner, Dds, LLC | HI | Pediatric Dentistry | $0 | $304.4K |
| Richard Ries | HI | Clinical Psychologist | $0 | $232.8K |
| Gova LLC | HI | Clinic/Center | $0 | $165.3K |
| Transformational Living Centers | HI | Community/Behavioral Health Agency | $0 | $102.3K |
| Xiao Yang | HI | Internal Medicine Physician | $95.8K | $0 |
| Julie Chang | HI | Pulmonary Disease Physician | $78.5K | $0 |
| Gina Shimabukuro-araki | HI | Occupational Therapist | $18K | $0 |
| Stacy Uyekubo | HI | Psychiatry Physician | $16.8K | $0 |
| Abby Davis | HI | Occupational Therapist | $11.4K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.